(CMPS) Compass Pathways - Ratings and Ratios
Exchange: NASDAQ • Country: United Kingdom • Currency: USD • Type: Common Stock • ISIN: US20451W1018
CMPS: Psilocybin, Therapy, Treatment
COMPASS Pathways plc (NASDAQ:CMPS) is a mental health care company focused on developing innovative treatments for mental health disorders. The company is currently advancing COMP360, a psilocybin-based therapy, through late-stage clinical trials. COMP360 is in Phase III trials for treatment-resistant depression (TRD) and has shown promising results in addressing this debilitating condition. Additionally, the therapy is in Phase II trials for post-traumatic stress disorder (PTSD) and anorexia nervosa, expanding its potential applications in mental health care. Formerly known as COMPASS Rx Limited, the company rebranded as COMPASS Pathways plc in August 2020 and is listed on the NASDAQ stock exchange. Headquartered in London, the company has established a strong presence in both the UK and the US, leveraging its research-driven approach to develop groundbreaking mental health treatments. https://compasspathways.com
Over the next three months, COMPASS Pathways plc (NASDAQ:CMPS) is expected to experience volatility due to its current position below its 20-day, 50-day, and 200-day moving averages (SMA 20: $4.30, SMA 50: $4.08, SMA 200: $5.87). The stocks average trading volume of 1.2 million shares over the last 20 days, combined with its ATR of 0.39, suggests moderate price fluctuations. From a fundamental perspective, the companys negative return on equity (RoE: -74.91) and high price-to-book (P/B: 2.17) ratio indicate significant investment in growth initiatives despite current losses. The lack of forward P/E suggests uncertainty about future profitability. The stock is likely to face resistance at $4.30 and support at $3.50, with potential sideways trading in the near term.
Additional Sources for CMPS Stock
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
CMPS Stock Overview
Market Cap in USD | 347m |
Sector | Healthcare |
Industry | Medical Care Facilities |
GiC Sub-Industry | Health Care Services |
IPO / Inception | 2020-09-18 |
CMPS Stock Ratings
Growth 5y | -89.9% |
Fundamental | -40.9% |
Dividend | 0.0% |
Rel. Strength Industry | -67.2 |
Analysts | 4.6/5 |
Fair Price Momentum | 1.91 USD |
Fair Price DCF | - |
CMPS Dividends
No Dividends PaidCMPS Growth Ratios
Growth Correlation 3m | -18.8% |
Growth Correlation 12m | -92% |
Growth Correlation 5y | -91.9% |
CAGR 5y | -37.62% |
CAGR/Max DD 5y | -0.40 |
Sharpe Ratio 12m | -1.09 |
Alpha | -78.27 |
Beta | 1.68 |
Volatility | 68.51% |
Current Volume | 664.4k |
Average Volume 20d | 1082.6k |
As of March 14, 2025, the stock is trading at USD 3.49 with a total of 664,434 shares traded.
Over the past week, the price has changed by -13.18%, over one month by -21.04%, over three months by -17.30% and over the past year by -67.26%.
Probably not. Based on ValueRay Fundamental Analyses, Compass Pathways (NASDAQ:CMPS) is currently (March 2025) not a good stock to buy. It has a ValueRay Fundamental Rating of -40.91 and therefor a somewhat negative outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of CMPS as of March 2025 is 1.91. This means that CMPS is currently overvalued and has a potential downside of -45.27%.
Compass Pathways has received a consensus analysts rating of 4.60. Therefor, it is recommend to buy CMPS.
- Strong Buy: 6
- Buy: 4
- Hold: 0
- Sell: 0
- Strong Sell: 0
According to ValueRays Forecast Model, CMPS Compass Pathways will be worth about 2.2 in March 2026. The stock is currently trading at 3.49. This means that the stock has a potential downside of -36.68%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 17.6 | 403.2% |
Analysts Target Price | 21.2 | 508% |
ValueRay Target Price | 2.2 | -36.7% |